Monopar Therapeutics has announced promising results from the Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline), demonstrating significant neurologic benefits for patients with Wilson disease who exhibit neurologic symptoms at baseline. Presented at the American Academy of Neurology (AAN) Annual Meeting 2026, the findings indicate that ALXN1840 not only improves neurologic outcomes but also reduces the likelihood of clinical deterioration compared to standard of care (SoC). Specifically, 45% of patients treated with ALXN1840 experienced clinically meaningful improvement at Week 48, compared to 32% on SoC, while only 9% of ALXN1840 patients showed significant worsening versus 25% in the SoC group (p=0.038).

These results underscore the therapeutic potential of ALXN1840 in addressing the unmet needs of Wilson disease patients. The trial data suggest that ALXN1840 provides a durable neurologic benefit, with improvements observed over a treatment duration of up to three years. The drug also demonstrated a favorable safety profile, with serious adverse events occurring in only 4.9% of patients, highlighting its viability as a long-term treatment option. The mechanism of action involves rapid mobilization and sequestration of excess copper, which is critical given the pathophysiology of Wilson disease characterized by copper accumulation.

The implications of these findings are significant for the field of neurology and rare genetic disorders. ALXN1840’s demonstrated efficacy could shift the treatment paradigm for Wilson disease, potentially leading to a New Drug Application (NDA) submission to the FDA in mid-2026. This advancement may accelerate research into other novel therapies targeting similar mechanisms of action, thereby influencing drug development timelines and strategies within the broader context of neurodegenerative diseases.

Source: globenewswire.com